Brandywine Managers LLC Purchases Shares of 9,510 Moderna, Inc. $MRNA

Brandywine Managers LLC purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 9,510 shares of the company's stock, valued at approximately $666,000.

A number of other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new stake in Moderna in the first quarter valued at approximately $415,000. NewEdge Advisors LLC increased its position in shares of Moderna by 732.7% during the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company's stock worth $328,000 after purchasing an additional 10,185 shares in the last quarter. United Services Automobile Association acquired a new position in shares of Moderna during the first quarter worth $230,000. Focus Partners Wealth lifted its holdings in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock valued at $668,000 after purchasing an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Moderna by 5.2% during the 2nd quarter. American Century Companies Inc. now owns 48,859 shares of the company's stock valued at $1,348,000 after purchasing an additional 2,410 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Down 4.3%

MRNA stock opened at $138.89 on Tuesday. The firm's fifty day simple moving average is $70.22 and its 200-day simple moving average is $56.87. The company has a market capitalization of $55.45 billion, a P/E ratio of -17.38 and a beta of 0.91. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm's revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the company posted ($2.13) earnings per share. As a group, equities research analysts forecast that Moderna, Inc. will post -6.18 earnings per share for the current year.

Insider Activity

In other news, President Stephen Hoge sold 53,336 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company's stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company's stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is currently owned by company insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck’s personalized mRNA cancer vaccine, intismeran autogene, delivered a positive Phase 3 result in melanoma when used with Keytruda. The result marks an important validation of Moderna’s mRNA platform and could support a substantial long-term oncology opportunity. Should You Buy Moderna Stock Following Its Cancer Breakthrough?
• Positive Sentiment: The cancer-vaccine success has strengthened investor confidence in Moderna’s pipeline and helped drive a major re-rating of MRNA. Management believes intismeran autogene could have significant long-term potential, while Moderna’s recently approved mRNA flu vaccine provides another commercial opportunity. Moderna Is Betting Big on Its Cancer Vaccine
• Neutral Sentiment: Analysts and investors are now focused on the next steps: regulatory submissions, durability of the clinical benefit, manufacturing capacity, pricing, and adoption. The Phase 3 result is significant, but commercialization and revenue generation remain several steps away. Why Moderna’s and Merck’s Cancer Vaccine Is a Breakthrough for mRNA
• Negative Sentiment: After an approximately 392% year-to-date surge, traders locked in gains across biotech and pharmaceutical stocks. With no fresh clinical or regulatory announcement to extend the advance, Moderna and related names cooled. Myriad Genetics and Moderna Shares Plummet, What You Need To Know
• Negative Sentiment: Investors remain concerned that personalized cancer vaccines may be difficult to manufacture at scale, less broadly applicable, and less lucrative than current enthusiasm suggests. Moderna also faces pipeline execution risks, competition, and intensifying Chinese investment in mRNA biotechnology. Moderna’s mRNA Cancer Vaccine Marks a Major Leap in Personalized Oncology

Analyst Ratings Changes

MRNA has been the topic of several research analyst reports. Morgan Stanley boosted their target price on Moderna from $39.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 20th. JPMorgan Chase & Co. increased their price target on Moderna from $40.00 to $77.00 and gave the company an "underweight" rating in a research note on Friday. UBS Group raised their price target on Moderna from $50.00 to $150.00 and gave the stock a "neutral" rating in a report on Thursday. Brookline Capital Markets restated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Finally, Royal Bank Of Canada restated a "sector perform" rating and set a $130.00 price objective on shares of Moderna in a report on Wednesday, August 19th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $74.31.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source